We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Detects Abnormalities in Developing Fetus

By LabMedica International staff writers
Posted on 08 Jul 2010
A cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy.

Dutch scientists are developing a prenatal blood test that would be able to detect accurately chromosomal abnormalities in the developing fetus. More...
At present, the only reliable way to do this is through amniocentesis or chorionic villus sampling, which is invasive and carries the risk of triggering a miscarriage.

Dr. Suzanna Frints, a clinical geneticist at Maastricht University Medical Center (Maastricht, The Netherlands) and colleagues have been able to use molecular-genetics probes to detect DNA belonging to the fetus in blood samples taken from pregnant women.

The team used the Multiplex Ligation-dependent Probe Amplification (MLPA), technique to detect fetal DNA that is present in the blood of women who have been pregnant for at least six to eight weeks. The MLPA test is part of an existing kit that is already used around the world to detect chromosomal abnormalities in invasively obtained amniotic fluid or chorionic villi samples from pregnant women.

The kit is cheap and fast, delivering results within 24-62 hours, but until now, it has only been used on samples taken during invasive procedures; it was not known whether it would work on cell free fetal DNA circulating in blood samples of pregnant women.

The scientists have been successful in identifying DNA from the Y chromosome, indicating that the fetus is a boy and could be at risk of inheriting an X-linked disorder such as Duchenne's muscular dystrophy and hemophilia.

The scientists believe the same method can be used to detect trisomy 21 (where an extra chromosome 21 causes Down's syndrome) and they are investigating this next, followed by trisomy 13 and 18 (responsible for causing Patau and Edward's syndromes respectively).

Dr. Frints said, "At the moment, the reliability of the test is about 80% due to false negative results, but we are working to improve the accuracy of the MLPA probe . Although we need to test and refine this MLPA technique further, our results so far are promising."

The work was presented at the 26th annual meeting of the European Society of Human Reproduction and Embryology in Rome (Italy) on June 29, 2010.

Related Links:

Maastricht University Medical Center



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.